Bernstein analyst William Pickering maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $310.00.

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Cogent Biosciences (COGT – Research Report) today and set a price target ...

The newly approved medicines in 2024 from Massachusetts companies range from a schizophrenia drug to a gene therapy for ...

More downtown commercial landlords challenged the city’s assessment of their building values, though Boston tax officials ...

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced that Chief Executive Officer, Madan Jagasia, M.D., will present at ...

Stuart Orkin, a paediatric haematologist and oncologist at the Harvard Stem Cell Institute in Cambridge ... to its developers, Vertex Pharmaceuticals in Boston, Massachusetts, and CRISPR ...

But positive early results from a trial run by the drug company Vertex Pharmaceuticals based in Boston, Massachusetts ... in 2014 at Harvard University in Cambridge 2. Now at Vertex, he is ...

It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals ... 2010 and is headquartered in Cambridge, Massachusetts. AbbVie Inc. discovers, develops, ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56, with a -0.62% movement compared to the previous day. This change was narrower than the S&P 500's 1.54% loss on the day.

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $402.49, demonstrating a -1.13% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.55%.

Vertex Pharmaceuticals’ Death Cross signals a bearish trend as shares fall below all critical moving averages. Clinical trial disappointments and technical sell signals pressure VRTX ...